Plain-English translation of NCT05020236 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called for people with multiple myeloma (a blood cancer) that has come back or stopped responding to previous treatments. Researchers want to know whether this medication works better when given alone, when combined with another antibody medicine, or compared to a standard combination of three drugs. The medication is designed to work by connecting immune cells directly to cancer cells.
Multiple myeloma often returns or becomes resistant to standard treatments, leaving patients with few good options. This trial is testing whether this medication could offer a better, more effective way to treat the disease when it recurs, potentially with fewer side effects than current approaches.
You likely qualify if…
You likely don't qualify if…
The study has multiple phases. In the first phase, researchers test different doses of the medication combined with another antibody to find the safest dose. In the second phase, you would be randomly assigned to receive one of three treatments: the new medication alone, the new medication combined with another antibody, or a standard three-drug combination. In the third phase, researchers add extra measures to protect against infection. You would continue receiving your assigned treatment until your cancer progresses, you experience unacceptable side effects, or you decide to stop.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States